MedTrace Logo

A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 Diabetes

NCT02765204 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2016-12-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate if Dapagliflozin has direct effect on alpha cell glucagon release.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Dapagliflozin

DRUG

Saxagliptin

DRUG

Glucose

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Uppsala University

    lead OTHER

Principal Investigators

  • Jan W Eriksson, MD PhD · Uppsala University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02765204 on ClinicalTrials.gov